Cohort (n=2,410)
Yes
Answers are grounded in this paper and cite their sources.
A 30% to 53% decrease in eGFR over 1 to 2 years is strongly associated with an increased risk of end-stage renal disease in Japanese patients with chronic kidney disease, supporting its use as a surrogate endpoint in clinical trials.
In the clinical phase of drug development, it is important to establish appropriate endpoints. In general, to verify hard endpoints such as death, many subjects need to be studied over a long period of time, resulting in a large-scale clinical trial. To promote the early development of drugs, it is essential to establish methods for evaluating the clinical usefulness of treatment drugs by predicting long-term prognosis utilizing methods such as appropriate surrogate endpoints. In the field of nephrology, treatment of chronic diseases such as chronic kidney disease (CKD) and diabetic kidney disease (DKD) is not satisfactory, and demands for the development of new drugs are strong. In Europe and the US, the use of surrogate endpoints for such diseases is being debated. Based on this situation, the “Research Working Group for Establishing Guidelines for Clinical Evaluation of CKD” was set up as a research funded by the Research on Regulatory Science of Pharmaceuticals and Medical Devices of the Japan Agency for Medical Research and Development (AMED). In this program, the Japanese Society of Nephrology and Japanese Society of Diabetes worked together to establish guidelines for the clinical evaluation of treatment drugs for CKD, in collaboration with the Pharmaceuticals and Medical Devices Agency, analyzed data of Japanese cohorts. The aim of the project is to enable appropriate and prompt approval review of newly developed drugs without discrepancy from international criteria based on evidence for Japanese CKD patients. In 2018, Japanese Society of Nephrology established the Research Working Group for Establishing Guidelines for Clinical Evaluation of CKD, which published “Guidelines for Clinical Evaluation of Chronic Kidney Disease” in the Japanese Journal of Nephrology, 2018, vol. 60, issue 2, 67–100. This is the English version of that report. Chairman: Naoki Kashihara.
No takes yet. Share an insight, caveat, or question.
Kanda et al. (2018) conducted a cohort in Chronic Kidney Disease (n=2,410). 53% decrease in eGFR over 1 year vs. Moderate or no change in eGFR (> -30 to ≤ 0%) was evaluated on End-stage renal disease (ESRD) (aHR 20.72, 95% CI 14.27-30.09).
Synapse has enriched 10 related papers. Consider them for comparative context: